Evolus Announces Presentation of Phase III Comparative Data of PrabotulinumtoxinA and OnabotulinumtoxinA

IRVINE, Calif., Feb. 16, 2018 /PRNewswire/ -- Evolus, Inc. (NASDAQ: EOLS) today announced the presentation of data from the Phase III comparative clinical trial of its investigational prabotulinumtoxinA 900 kilodalton (kDa) neuromodulator at the American Academy of Dermatology (AAD) meeting. Results from the European and Canadian Phase III study, EVB-003, will be presented by one of the study investigators Berthold Rzany, M.D., during the AAD Meeting in San Diego on Saturday, February 17 at 10:12 AM in room 6D.  

About PrabotulinumtoxinA

PrabotulinumtoxinA is a 900 kDa purified botulinum toxin type A complex.  The product candidate's Biologics License Application (BLA) is currently under review by the U.S. Food and Drug Administration (FDA).  The product candidate's Marketing Authorization Application (MAA) is currently also under review by the European Medicines Agency (EMA). The FDA application is for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adults.  The EMA application is for temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown (glabellar lines), when the severity has an important psychological impact in adult patients.

About Evolus, Inc.

Evolus, Inc. is a medical aesthetics company focused on providing physicians and their patients with expanded choices in aesthetic procedures and treatments. Evolus, Inc. focuses on the self-pay aesthetic market and our lead product candidate is an injectable 900 kDa purified botulinum toxin type A complex.

Evolus Press Contacts:

September Riharb, Vice President, Marketing 
Tel: +1-805-764-6300
Email: [email protected]

Jeff Plumer, Vice President, Legal
Tel: +1-949-284-4555
Email: [email protected]

SOURCE Evolus, Inc.

Related Links

http://www.evolus.com